Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Clearance Models: Noncompartmental Models

Clearance Models: Noncompartmental Models

Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...

Clearance Models: Physiological Models

Clearance Models: Physiological Models

Drug clearance is a critical pharmacokinetic process involving the irreversible removal of drugs from the body through various organs over a specified time period. Physiological models are indispensable in determining organ-specific clearance, defined by the proportion of the drug eliminated per unit of time from the organ's blood volume.
The organ's clearance rate depends on the blood flow to the organ and the extraction ratio (E). The extraction ratio describes the organ's proficiency in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systematic Screening of Occupational Exposures in patients with prostate or kidney cancer.

The French journal of urology·2026

Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026

Same author

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA oncology·2026

Same author

Prospective registry for patients undergoing artificial urinary sphincter surgery for female stress urinary incontinence due to intrinsic sphincter deficiency: Study protocol.

The French journal of urology·2026

Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026

Same author

Outcomes of inguinal hernia repair after implantation of preperitoneal reservoir for artificial urinary sphincter or penile implant.

BMC surgery·2026

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA

Benoit You¹, Paul Perrin, Gilles Freyer

¹Université de Lyon, Lyon, F-69003, France. benoit.you@chu-lyon.fr

Clinical Biochemistry

|April 29, 2008

Summary

This summary is machine-generated.

A new population kinetic model using prostate-specific antigen (PSA) clearance (CL(PSA)) offers a superior method for tracking PSA levels post-prostate surgery compared to traditional half-life models.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jul 5, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

Pharmacokinetics
Urology
Oncology

Background:

Prostate-specific antigen (PSA) levels are crucial for monitoring prostate cancer recurrence after surgery.
Traditional methods using half-life models may not fully capture the complex PSA decrease profile.

Purpose of the Study:

To compare a population kinetic model based on PSA clearance (CL(PSA)) with multi-exponential models for characterizing post-adenomectomy PSA decline.
To evaluate the CL(PSA) model's performance in predicting biochemical relapse.

Main Methods:

A population kinetic model and a multi-exponential model were developed using NONMEM software.
Data from 182 post-adenomectomy PSA concentrations in 56 benign prostatic hyperplasia patients were analyzed.

Main Results:

The CL(PSA) model demonstrated superior performance over multi-exponential models based on Akaike information criteria and standard errors.
The CL(PSA) model was defined as CL(PSA)=0.0229()(AGE/69)(3.78).
A threshold of 2 ng/mL on day 90 was identified for diagnosing biochemical relapse.

Conclusions:

The population CL(PSA) model provides a more rational and accurate strategy for assessing individual PSA decrease profiles after prostate surgery.
This approach enhances the ability to monitor treatment effectiveness and detect relapse.